TY - JOUR
T1 - TGF-β2 reduces demyelination, virus antigen expression, and macrophage recruitment in a viral model of multiple sclerosis
AU - Drescher, Kristen M.
AU - Murray, Paul D.
AU - Lin, Xiaoqi
AU - Carlino, Joseph A.
AU - Rodriguez, Moses
PY - 2000/3/15
Y1 - 2000/3/15
N2 - TGF-β2 is a potent immunoregulatory mediator that influences B cell, T cell, and macrophage function. To test whether this cytokine alters pathology in a model of virus-induced demyelinating disease, we treated SJL/J mice with TGF-β2 either before or after infection with Theiler's murine encephalomyelitis virus. Treatment continued three times weekly through day 35 postinfection. TGF-β2 administration resulted in significantly smaller lesions and fewer virus Ag-positive cells in the spinal cords of infected SJL/J mice. Mice treated with TGF-β2 had similar levels of virus-specific IgG as infected, control-treated mice. TGF-β2 administration significantly increased the level of non-virus-specific activated CTLs, but had no effect on virus-specific CTLs. TUNEL revealed a decrease in the number of apoptotic nuclei in the spinal cord white matter of mice treated in vivo with TGF-β2. Immunostaining with an Ab to F4/80 revealed that TGF-β2-treated mice had significantly fewer F4/80-positive cells in the white matter of the spinal cord as compared with infected control-treated mice. These data suggest that TGF-β2 may control virus-induced demyelination via an immunomodulatory mechanism that reduces macrophage infiltration.
AB - TGF-β2 is a potent immunoregulatory mediator that influences B cell, T cell, and macrophage function. To test whether this cytokine alters pathology in a model of virus-induced demyelinating disease, we treated SJL/J mice with TGF-β2 either before or after infection with Theiler's murine encephalomyelitis virus. Treatment continued three times weekly through day 35 postinfection. TGF-β2 administration resulted in significantly smaller lesions and fewer virus Ag-positive cells in the spinal cords of infected SJL/J mice. Mice treated with TGF-β2 had similar levels of virus-specific IgG as infected, control-treated mice. TGF-β2 administration significantly increased the level of non-virus-specific activated CTLs, but had no effect on virus-specific CTLs. TUNEL revealed a decrease in the number of apoptotic nuclei in the spinal cord white matter of mice treated in vivo with TGF-β2. Immunostaining with an Ab to F4/80 revealed that TGF-β2-treated mice had significantly fewer F4/80-positive cells in the white matter of the spinal cord as compared with infected control-treated mice. These data suggest that TGF-β2 may control virus-induced demyelination via an immunomodulatory mechanism that reduces macrophage infiltration.
UR - http://www.scopus.com/inward/record.url?scp=0034653933&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034653933&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.164.6.3207
DO - 10.4049/jimmunol.164.6.3207
M3 - Article
C2 - 10706712
AN - SCOPUS:0034653933
SN - 0022-1767
VL - 164
SP - 3207
EP - 3213
JO - Journal of Immunology
JF - Journal of Immunology
IS - 6
ER -